Literature DB >> 2920218

Expression of nonspecific cross-reacting antigen species in myeloid leukemic patients and healthy subjects.

A Noworolska1, A Harłozińska, F Buchegger, B Lawińska, R Richter.   

Abstract

The reactivity of two monoclonal antibodies recognizing NCA-95 and NCA-55 (MAb 47 and MAb 192, respectively) with a polyclonal anti-NCA serum in myeloid leukemic cells isolated by density gradient centrifugation was compared using an immunofluorescence test (IF). It was observed that the blood myeloid cells in 78.8% of the patients with different types of myelocytic leukemias and all granulocytes of 15 normal donors showed similar expression of the NCA species studied. The leukocytes of the remaining patients did not synthesize the NCA-95 species regardless of the maturation stage of the cells studied. In two patients, synthesis of this NCA form was limited to the fractions containing myelocytes and metamyelocytes. We have found that all anti-NCA antibodies studied recognized different antigenic epitopes in a myeloid cell series. A relationship between the patient's survival and the proportion of NCA-containing cells was also observed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2920218     DOI: 10.1007/BF00320651

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  11 in total

1.  Two CEA and three NCA species, although distinguishable by monoclonal antibodies, have nearly identical peptide patterns.

Authors:  F Grunert; N AbuHarfeil; K Schwarz; S von Kleist
Journal:  Int J Cancer       Date:  1985-09-15       Impact factor: 7.396

2.  Monoclonal antibody against carcinoembryonic antigen (CEA) identifies two new forms of crossreacting antigens of molecular weight 90,000 and 160,000 in normal granulocytes.

Authors:  M Audette; F Buchegger; M Schreyer; J P Mach
Journal:  Mol Immunol       Date:  1987-11       Impact factor: 4.407

3.  Distribution of surface nonspecific cross-reacting antigen and influence of proteolytic enzymes on this antigen in myeloid cell series.

Authors:  A Noworolska; A Harłozińska-Szmyrka; R Richter
Journal:  Cancer Detect Prev       Date:  1986

4.  Monoclonal antibodies identify a CEA crossreacting antigen of 95 kD (NCA-95) distinct in antigenicity and tissue distribution from the previously described NCA of 55 kD.

Authors:  F Buchegger; M Schreyer; S Carrel; J P Mach
Journal:  Int J Cancer       Date:  1984-05-15       Impact factor: 7.396

5.  The subunit structure of non-specific cross-reacting antigen (NCA).

Authors:  A Krop-Watorek; P Sedlaczek; E Lisowska
Journal:  Mol Immunol       Date:  1983-07       Impact factor: 4.407

6.  Characterization of monoclonal antibodies to carcinoembryonic antigen with increased tumor specificity.

Authors:  S Jothy; S A Brazinsky; M Chin-A-Loy; A Haggarty; M J Krantz; M Cheung; A Fuks
Journal:  Lab Invest       Date:  1986-01       Impact factor: 5.662

7.  Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epitopes detectable on carcinoembryonic antigen (CEA).

Authors:  K Bosslet; G Lüben; A Schwarz; E Hundt; H P Harthus; F R Seiler; C Muhrer; G Klöppel; K Kayser; H H Sedlacek
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

8.  Clinical evaluation of NCA in patients with chronic myelocytic leukemia.

Authors:  B Wahren; G Gahrton; U Rudén; S Hammarström
Journal:  Int J Cancer       Date:  1982-02-15       Impact factor: 7.396

9.  High and low Fc IgG-receptor expression in human chronic granulocytic leukaemia cells.

Authors:  A Harłozińska; J Potomski; B Lawinska; A Noworolska; R Richter
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

10.  Non-specific cross-reacting antigen (NCA) in individual maturation stages of myelocytic cell series.

Authors:  A Noworolska; A Harłozińska; R Richter; W Brodzka
Journal:  Br J Cancer       Date:  1985-03       Impact factor: 7.640

View more
  2 in total

Review 1.  Recent advances in bone marrow scanning.

Authors:  S N Reske
Journal:  Eur J Nucl Med       Date:  1991

2.  A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.

Authors:  Inga Buchmann; Thomas Kull; Gerhard Glatting; Donald Bunjes; Geoffrey Hale; Jorg Kotzerke; Dirk Rattat; Hartmut Dohner; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-22       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.